VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+4.9%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$31.7M
Cap. Flow
% of AUM
11.98%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| 1 |
DT Midstream
DTM
|
$1.86M |
| 2 |
ScottsMiracle-Gro
SMG
|
$878K |
| 3 |
Valero Energy
VLO
|
$790K |
| 4 |
FMC
FMC
|
$775K |
| 5 |
Delek US
DK
|
$761K |
Top Sells
| 1 |
COR
Coresite Realty Corporation
COR
|
$1.67M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
$551K |
| 4 |
Travere Therapeutics
TVTX
|
$479K |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$448K |
Sector Composition
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Sangamo Therapeutics
SGMO
$160M
| $167K | 0.06% |
22,227
+4,141
| +23% | +$31.1K |
|
302
Shattuck Labs
STTK
$72.3M
| $167K | 0.06% |
19,648
+12,186
| +163% | +$104K |
|
|
TVRD
303
Tvardi Therapeutics, Inc. Common Stock
TVRD
$285M
| $167K | 0.06% |
381
-30
| -7% | -$13.2K |
|
304
BioXcel Therapeutics
BTAI
$52M
| $166K | 0.06% |
510
+163
| +47% | +$53.1K |
|
305
Codexis
CDXS
$218M
| $166K | 0.06% |
5,315
-4,550
| -46% | -$142K |
|
|
ARNA
306
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $166K | 0.06% |
1,785
-1,393
| -44% | -$130K |
|
307
Atara Biotherapeutics
ATRA
$89.9M
| $165K | 0.06% |
418
-162
| -28% | -$63.9K |
|
308
GH Research
GHRS
$872M
| $165K | 0.06% |
+7,086
| New | +$165K |
|
309
KalVista Pharmaceuticals
KALV
$765M
| $165K | 0.06% |
12,482
+4,988
| +67% | +$65.9K |
|
310
PMV Pharmaceuticals
PMVP
$76.3M
| $165K | 0.06% |
7,151
+922
| +15% | +$21.3K |
|
|
NGM
311
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $165K | 0.06% |
9,301
-1,623
| -15% | -$28.8K |
|
|
CLVS
312
DELISTED
Clovis Oncology, Inc.
CLVS
| $165K | 0.06% |
60,836
+24,426
| +67% | +$66.2K |
|
313
Invivyd
IVVD
$209M
| $164K | 0.06% |
+22,625
| New | +$164K |
|
314
Lexicon Pharmaceuticals
LXRX
$389M
| $164K | 0.06% |
41,584
-2,794
| -6% | -$11K |
|
|
GTHX
315
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $164K | 0.06% |
16,088
+6,745
| +72% | +$68.8K |
|
316
AC Immune
ACIU
$216M
| $163K | 0.06% |
32,852
+4,158
| +14% | +$20.6K |
|
317
Cullinan Oncology
CGEM
$408M
| $163K | 0.06% |
10,536
+3,611
| +52% | +$55.9K |
|
318
Krystal Biotech
KRYS
$4.33B
| $163K | 0.06% |
2,336
-952
| -29% | -$66.4K |
|
319
Scholar Rock
SRRK
$3.12B
| $163K | 0.06% |
6,578
-46
| -0.7% | -$1.14K |
|
320
Denali Therapeutics
DNLI
$2.16B
| $162K | 0.06% |
3,633
+803
| +28% | +$35.8K |
|
321
MacroGenics
MGNX
$123M
| $162K | 0.06% |
10,120
-93
| -0.9% | -$1.49K |
|
322
Replimune Group
REPL
$454M
| $162K | 0.06% |
5,986
-148
| -2% | -$4.01K |
|
323
Alector
ALEC
$285M
| $161K | 0.06% |
7,799
-2,240
| -22% | -$46.2K |
|
324
Athira Pharma
ATHA
$15.3M
| $160K | 0.06% |
12,249
+1,293
| +12% | +$16.9K |
|
325
Instil Bio
TIL
$205M
| $160K | 0.06% |
+466
| New | +$160K |
|